MicroRNA deregulation and pathway alterations have been implicated in nasopharyngeal carcinoma (NPC), a highly invasive and metastatic cancer widely prevalent in Southern China. In this study, we report that miR-9 is commonly downregulated in NPC specimens and NPC cell lines with important functional consequences. The reduced expression of miR-9 was inversely correlated with clinical stages and marked the progression from locoregional to metastatic tumors. The CpG island hypermethylation contributed to miR-9 silencing in NPC cell lines and tissues. Ectopic expression of miR-9 dramatically inhibited the proliferative, migratory and invasive capacities of NPC cells in vitro and in vivo. We found that miR-9 strongly reduced the expression of CXCR4 in NPC cells. Luciferase assay demonstrated that miR-9 could directly bind to the 3′ untranslated region of CXCR4. Similar to the restoring miR-9 expression, CXCR4 downregulation inhibited cell growth, migration and invasion, whereas CXCR4 overexpression rescued the suppressive effect of miR-9. Mechanistic investigations revealed that CXCR4 functionally mediated the SDF-1-stimulated activation of p38 mitogen-activated protein kinase pathway in NPC cells with miR-9 downregulation or CXCR4 overexpression. In clinical specimens, CXCR4 and phospho-p38 were widely overexpressed, and the levels increased with the progression from locoregional to metastatic tumors in NPC tissues. The levels of CXCR4 were inversely correlated with miR-9 or phospho-p38 expression. Taken together, our results indicate that miR-9 functions as a tumor-suppressive microRNA in NPC, and that its suppressive effects are mediated chiefly by repressing CXCR4 expression.
Introduction
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous cell carcinoma, which occurs in the epithelial lining of the nasopharynx. The highest prevalence of this cancer was reported in Southern China (20-50 cases per 100 000 individuals), however, in Western Europe and USA, the lowest prevalence was estimated in 0.5 cases per 100 000 individuals (1) . Compared with other head and neck squamous cell carcinomas, the NPC patients tend to present at a more advanced stage with higher metastatic potential, and 30-60% of patients with NPC will eventually develop distant metastasis and die of disseminated disease (2) . During tumorigenesis and progression, multiple genetic and epigenetic abnormalities synergistically disrupt normal cell function, thus contributing to NPC pathogenesis. Therefore, further identification and characterization of new targets may clarify the specific molecular events involved in NPC initiation, promotion and progression.
MicroRNAs (miRNAs) are small non-coding RNAs, which inhibit gene expression by interacting with the 3′ untranslated regions (3′UTRs) of target mRNAs (3) . There is a large body of evidence that miRNAs can function as oncogenes or tumor suppressors and contribute to tumorigenesis (4, 5) . Although a large number of miRNAs have been identified to date, the precise contribution of miRNAs to tumorigenesis and the mechanism underlying their dysregulation remain largely unknown. Accumulated evidence has shown that epigenetic silencing of miRNAs with tumor suppressor features by CpG island hypermethylation is emerging as a common hallmark of human cancers (6) . Recently, several miRNAs have been identified as an oncogene or a tumor suppressor to regulate the development and progression of NPC, such as miR-144, 18a, 138 and 216b (7) (8) (9) (10) . These miRNAs and their target genes comprise a complicated network, which plays a critical role in NPC pathogenesis.
MiR-9 is emerging as a critical regulator of organ development and neurogenesis (11) . There are also many reports of aberrant miR-9 expression in several cancers. The role of miR-9 in cancer cells seems controversial as it serves as a metastasis-promoting miRNA in breast cancer (12) but a tumor suppressor in melanoma (13) . The reduced expression of miR-9 is considered as a poor survival marker in cervical cancer (14) , lung squamous cell carcinoma (15) and acute lymphoblastic leukemia (16) . Silencing of miR-9 by CpG island hypermethylation has been found in many tumors (15) (16) (17) (18) (19) (20) , clearly indicating that miR-9 possesses tumor suppressor features. However, the function of miR-9 in NPC pathogenesis, as well as the molecular mechanisms by which miR-9 exerts its functions and modulates the malignant phenotypes of NPC cells, has not been fully understood.
In this study, we clearly demonstrated that miR-9 functioned as a tumor suppressor miRNA. The tumor-suppressive effect was mediated by repressing CXCR4 and downstream p38 mitogen-activated protein kinase (MAPK) pathway. Thus, our findings provide valuable clues toward understanding the mechanisms of NPC pathogenesis and present an opportunity to develop new effective clinical therapies in future.
Materials and methods

Clinical samples
The NPC biopsy specimens (n = 276) and non-cancer nasopharyngitis biopsy samples (n = 114) were collected from Nanfang Hospital between 2006 and 2008. All samples were pathologically reassessed. The healthy donors were carefully selected to match the gender and age distribution of NPC patients. None of the patients had received radiotherapy or chemotherapy before biopsy sampling and blood collecting. The TNM classification was according to the definitions of the seventh edition of the UICC-American Joint Committee on Cancer staging criteria. Informed consent was obtained from all individuals, and the research protocols were approved by the Ethics Committee of Nanfang Hospital.
Cell culture
An immortalized nasopharyngeal epithelial cell NP69 was cultured in Keratinocyte-SFM (Invitrogen, Grand Island, NY) supplemented with bovine Abbreviations: DNMT, DNA methyltransferase; ISH, in situ hybridization; MAPK, mitogen-activated protein kinase; miRNA, microRNA; MSP, methylation-specific PCR; mt, mutant; NPC, nasopharyngeal carcinoma; PBS, phosphatebuffered saline; qPCR, quantitative PCR; UTR, untranslated region; wt, wild type. miR-9: a potential tumor suppressor pituitary extract (BD Biosciences, San Diego, CA). The human NPC cell lines 5-8F, 6-10B, CNE1, CNE2, C666-1, HONE1 and Sune-1 were cultured in RPMI-1640 (Invitrogen). HEK 293T cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen).
Constructs and plasmids
A 187 bp DNA fragment corresponding to pre-miR-9 and the flanking sequence was amplified from human genomic DNA and then cloned into pLVTHM lentiviral vector (http://www.addgene.org/Didier_Trono). The shRNA insert sequence of CXCR4 gene was designed as described previously (21) , and the fragment was inserted into pLVTHM vector. Another lentiviral vector pReceiver-Lv105-CXCR4-ORF (GeneCopoeia, MD) for cDNA delivery of CXCR4 was purchased. A 497 bp fragment of CXCR4 3′UTR was amplified by PCR and cloned downstream of the renilla luciferase gene in psiCHECK TM -2 vector (Promega). The vector was named wild-type (wt) 3′UTR. Site-directed mutagenesis of the miR-9 binding site in CXCR4 3′UTR was performed using GeneTailor Site-Directed Mutagenesis System (Invitrogen) and was named mutant (mt) 3′UTR.
Transfections and lentivirus transduction
Transient transfection of miR-9 mimic or inhibitor was performed using Lipofectamine 2000 reagent (Invitrogen). The production, concentration, purification and titration of lentivirus were performed as described by Tiscornia et al. (22) .
Immunohistochemistry and in situ hybridization
Immunohistochemical analysis of CXCR4 protein was performed as described previously (23) . Rabbit polyclonal anti-CXCR4 antibody (Abcam, Cambridge, UK) was diluted at 1:100. Immunohistochemical analysis of p38 and phosphop38 was performed as described by Lofgren et al. (24) . Total and phospho-p38 MAPK antibodies were purchased from Cell Signaling, MA. In situ detection of miR-9 on formalin-fixed paraffin-embedded samples was essentially performed with a miRCURY LNA™ miR-9 detection probe, using an ISH optimization kit (Exiqon, Vedbaek, Denmark) (25) . A scramble-miR probe (Exiqon) was performed as negative control.
RNA isolation and quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen). The expression of mature miRNA was determined using Taqman miRNA Assays (Applied Biosystems, Foster City, CA). U6 snRNA was used as an endogenous control. The mRNA levels of CXCR4, pri-miR-9-1, pri-miR-9-2 and pri-miR-9-3 were evaluated using SYBR Green PCR master mix (Applied Biosystems). The primers were listed in Supplementary 
Western blot analysis
Western blot analysis was performed using the following antibodies: anti-CXCR4 (Abcam), anti-glyceraldehyde 3-phosphate dehydrogenase (Santa Cruz biotechnology, CA), total p38 antibody (Cell Signaling) and phosphop38 antibody (Cell Signaling). Glyceraldehyde 3-phosphate dehydrogenase was used as a loading control.
Luciferase reporter assay
Luciferase reporter assay was performed as described previously (27) .
DNA methylation analysis
The CpG Island Searcher Program was used to determine the CpG island located in the promoter region of miR-9. For inhibition of DNA methyltransferase (DNMT) activity, cells were treated for 3 days in the presence of 5 µM 5-aza-2′-deoxycytidine (Sigma, Ronkonkoma, NY). DNA methylation status was examined as previously reported by Lujambio et al. (18) . The primers were listed in Supplementary Table 1, available at Carcinogenesis Online.
Cell proliferation assay, cell cycle analysis and colony formation assay
The effect of miR-9 on cell growth and viability was determined by MTT assay. The cell cycle distribution was analyzed by propidium iodide staining and flow cytometry. The colony formation assay was performed according to the protocol (28) .
In vitro migration and invasion assays
For Transwell migration assays, 2.5 × 10 4 cells were plated in the top chamber with the non-coated membrane (24-well insert; pore size: 8 µm; Corning, Corning, NY). For invasion assays, 5 × 10 4 cells were plated in the top chamber with Matrigel-coated membrane (24-well insert; pore size: 8 µm; BD Biosciences). In both assays, cells were plated in medium without serum, and medium supplemented with serum was used as a chemoattractant in the lower chamber. The cells were incubated for 12 h and cells that did not migrate or invade through the pores were removed by a cotton swab. Cells on the lower surface of the membrane were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet and counted.
Animal studies
Male BALB/c nude mice, 4-6 weeks old, were obtained from Centre of Laboratory Animal of Southern Medical University. The experiments were approved by Institutional Animal Care and Use Committee of Southern Medical University.
For tumor growth assay, Sune-1 cells were injected subcutaneously into the dorsal flank of nude mice (10 6 cells per mouse, five mice per group). After 1 week to allow tumor engraftment, lentivirus expressing miR-9 or negative control was delivered to the tumor site through direct intratumoral injection (1 × 10 8 transduction units, twice a week for 2 weeks). Tumor size was measured every 2 days. When mice were killed, tumors were dissected and the volumes were calculated as follows: volume = (D × d
2 )/2, where D meant the longest diameter and d meant the shortest diameter.
For tumor metastasis assay in vivo, we used a murine model of NPC metastasis successfully established previously (29) . To establish this model, we inoculated NPC cells into the liver as a single nodule, which would subsequently metastasized to other parts of the liver and the lung. A total of 18 mice were randomly divided into two groups (nine mice per group): (i) injection of C666-1/miR-9 cells and (ii) injection of C666-1/con cells. The mice were killed and autopsied on day 14, and the growth of primary xenografted tumor and the incidence of lung or liver metastasis were recorded.
Statistical analysis SPSS 13.0 software was used for statistical analysis. Data were presented as mean ± standard error of the mean of at least three independent experiments. Two-tailed Student's t-test was used for comparisons of two independent groups. Comparisons of multiple independent groups were analyzed using one-way analysis of variance followed by a Student-Newman-Keuls test. The relationships between CXCR4 and miR-9 or phospho-p38 expression were explored by Spearman's correlation. Prevalence of miR-9 promoter methylation and significant associations between miR-9 level and clinicopathological parameters were assessed by a chi-squared test. P values of <0.05 were considered statistically significant.
Results
Expression of miR-9 in NPC marks the progression from locoregional to metastatic tumors
To determine the clinicopathologic significance of the miR-9 aberration, we evaluated the expression level of miR-9 in 256 frozen NPC tissues and 104 non-cancer nasopharyngitis tissues using quantitative PCR (qPCR). miR-9 expression was not significantly associated with age and gender of the patients (Supplementary Table 2 , available at Carcinogenesis Online). However, miR-9 expression was significantly reduced in NPC tissues as compared with non-cancer nasopharyngitis tissues (P < 0.001; Figure 1A ). We also found that miR-9 expression was higher in stage 1 patients, whereas stages 2-4 had lower levels, showing a significant correlation of miR-9 level with clinical stages (P = 0.007; Figure 1B ; Supplementary Table 2, available at Carcinogenesis Online). The expression level of miR-9 in stage 1 tissues was significantly lower than in non-cancer nasopharyngitis tissues (P = 0.021; Figure 1B) . Remarkably, miR-9 expression in the subgroup of metastatic NPC patients (n = 229) was reduced by 50% compared with the group of locoregional NPC patients (n = 27) (P < 0.001; Figure 1C ). Moreover, in situ hybridization (ISH) detection of miR-9 in select tissue samples (20 control, 20 primary tumors of locoregionally advanced NPC, 20 primary tumors of metastatic NPC) further confirmed the above results ( Figure 1D and E). Taken together, these data provided strong evidence that the low miR-9 expression was closely related to the progression and metastasis of NPC.
Specific hypermethylation contributes to miR-9 silencing in NPC
A panel of human NPC cell lines was first analyzed to quantitate the expression level of miR-9. The results showed that the expression level of miR-9 was decreased in all seven NPC cell lines examined, compared with the immortalized non-tumorigenic cell line NP69 (Supplementary Figure 1 , available at Carcinogenesis Online). The mature hsa-miR-9 transcript is produced by three independent genes: mir-9-1 (1q22), mir-9-2 (5q14.3) and mir-9-3 (15q26). Previous studies showed that these miR-9 genes were commonly hypermethylated in cancer, which were associated with the development of metastasis (19) . Interested in learning more about the epigenetic modifications of these three miR-9 loci in NPC, we carried out methylation-specific PCR (MSP) analysis. The results showed that high frequency of DNA methylation in three mir-9 loci was detected in four NPC cell lines, and miR-9-3 loci was unmethylated in C666-1 cells (Figure 2A) . To demonstrate the transcriptional silencing of miR-9 loci in association with CpG island hypermethylation, C666-1 and Sune-1 cells were treated with a demethylating agent 5-aza. Our results found that demethylation treatment reactivated the transcriptional activities of mature miR-9, pri-miR-9-1, pri-miR-9-2 and pri-miR-9-3 in Sune-1 cells, whereas it could not restore pri-miR-9-3 expression in C666-1 cells ( Figure 2B ), consistent with the results of MSP analysis.
We then determined the methylation status in 20 NPC tissues in which miR-9 level decreased by >65% as compared with 10 control tissues ( Figure 2C ). We identified that miR-9 was mainly expressed from mir-9-2 by detecting its precursors in control tissues ( Figure 2D ), and pri-miR-9-2 expression was markedly decreased in NPC tissues, but pri-miR-9-1 expression was not altered ( Figure 2E ). Moreover, we ruled out the possibility that the three miR-9 loci were deleted in NPC genome, as equal amounts of them were detected in equal amounts of genomic DNA extracted from NPC and control tissues using qPCR (data not shown). MSP analysis showed that the frequency of miR-9 promoter methylation was higher in NPC tissues than in non-cancer nasopharyngitis biopsy tissues (mir-9-1: P = 0.333; mir-9-2: P = 0.004; mir-9-3: P < 0.001; Figure 2F ). Subsequent bisulfite sequencing data of selected samples further confirmed the above results (Supplementary Figure 2 , available at Carcinogenesis Online). We next examined whether miR-9 promoter methylation was associated with miR-9 silencing by investigating miR-9 expression using qPCR in above tissue samples. In accordance with the high frequency of DNA methylation in tumor tissues, we detected a significant downregulation of miR-9 expression in NPC tissues compared with non-cancer tissues (P < 0.001; Figure 2C and F). Therefore, we suggested that DNA hypermethylation resulted in miR-9 silencing in NPC cells and tissues, and mir-9-2 hypermethylation contributed more to miR-9 inactivation in NPC tissues.
miR-9 represses NPC growth and metastasis in vitro and in vivo
We next investigated the role of miR-9 in NPC tumorigenesis. In NPC cell lines C666-1 and Sune-1, miR-9 expression was markedly Figure 1, available at Carcinogenesis Online), and transfection of miR-9 mimics restored its expression in these cells ( Figure 3A) . Restoration of miR-9 expression repressed cell growth and inhibited cell cycle progression by induction of a G 1 phase arrest (Figure 3B and C; Supplementary Figure 3A , available at Carcinogenesis Online). Additionally, in miR-9 stably overexpressed C666-1 and Sune-1 cells, the colony formation rate was also significantly decreased ( Figure 3D and 3E ). More importantly, we found that ectopic expression of miR-9 strongly inhibited the migratory and invasive capacities of NPC cells by using Transwell migration and invasion assays (Figure 3F and G; Supplementary Figure 3B , available at Carcinogenesis Online).
To further investigate the suppressive effect of miR-9 in vivo, we prepared a human NPC-bearing mouse model by injecting Sune-1 cells to form subcutaneous transplantation tumor. After 1 week to allow tumor engraftment, LV-miR-9 or LV-con or phosphate-buffered saline (PBS) was delivered to the tumor site through direct intratumoral injection. At the end of the experiments, we found that the tumors in LV-contreated group and PBS group grew more rapidly and attained greater volumes than those in LV-miR-9-treated group (P < 0.001; Figure 4A and C), and the expression level of miR-9 was significantly elevated in the tumor tissues of LV-miR-9-treated group ( Figure 4B) .
The in vitro results led us to examine the influence of miR-9 overexpression in a murine model of NPC metastasis. Primary tumors were established by direct injection of LV-miR-9-infected or The expression of pri-miR-9-1, pri-miR-9-2 and pri-miR-9-3 was detected by qPCR in 10 non-cancer nasopharyngitis tissues. (E) Pri-miR-9-1, pri-miR-9-2 and pri-miR-9-3 expressions were examined by qPCR in 20 NPC tissues and 10 non-cancer nasopharyngitis tissues. (F) MSP and qPCR analyses were used to determine the methylation status and expression of miR-9 in above tumor and control tissues indicated in (C). N represents noncancer nasopharyngitis tissues and T represent NPC tissues. *P < 0.05, **P < 0.01 compared with control.
J.Lu et al.
LV-con-infected C666-1 cells into the liver. Fourteen days post-transplantation, the mice were killed and the livers and lungs were dissected for macroscopic and microscopic histology. Livers and lungs of mice bearing miR-9-expressing C666-1 tumors harbored statistically significantly fewer microscopic and macroscopic metastases than those of mice bearing mock-infected C666-1 tumors (P < 0.001; Figure 4D-F) .
miR-9 regulates CXCR4 and downstream p38 MAPK pathway
We used four computational algorithms, including miRanda, TargetScan, Pictar and miRBase, to predict the targets of miR-9. The data revealed that miR-9 could target evolutionarily conserved sequences present in CXCR4 mRNA ( Figure 5A ). In C666-1 cells with ectopic miR-9 expression, we found a pronounced reduction in CXCR4 protein expression compared with control ( Figure 5B ). Overexpression of miR-9 statistically significantly reduced the activity of a luciferase reporter fused to the wt CXCR4 3′UTR ( Figure 5C,  lanes 2 and 3) , but not the activity of a reporter fused to a mt CXCR4 3′UTR ( Figure 5C, lanes 7 and 8) . Meanwhile, cotransfection with miR-9 inhibitor and wt 3′UTR vector in C666-1 cells led to a 1.5-fold increase of luciferase activity ( Figure 5C, lanes 4 and 5) . All these data suggested that CXCR4 was a direct target of miR-9.
To further elucidate whether the tumor-suppressive effect of miR-9 was mediated by repression of CXCR4 in NPC cells, we established stable CXCR4-silenced and CXCR4-overexpressed C666-1 cells, respectively. Similar to miR-9 overexpression, we found that reduced expression of CXCR4 significantly inhibited cell proliferation, migration and invasion, similar to those induced by miR-9 (Supplementary Figure 4A , available at Carcinogenesis Online). In contrast, ectopic expression of CXCR4 using a CXCR4 expression vector, which encoded the entire coding sequence without the 3′UTR, significantly abrogated the tumor-suppressive effect induced by miR-9 (Supplementary Figure 4B , available at Carcinogenesis Online), indicating that the tumor-suppressive effects of miR-9 were chiefly mediated by repressing CXCR4 expression.
We summarized the predicted targets of miR-9 and identified the 53 top candidates, which were common to all four database (Supplementary Figure 5A , available at Carcinogenesis Online). These predicted target genes were subjected to enrichment analysis of cell signaling pathways using KEGG pathway database (http://www. genome.jp/kegg/). The MAPK signaling pathway was found to be significantly enriched by the predicted targets of miR-9 (Supplementary Figure 5B , available at Carcinogenesis Online). Previous studies showed that the binding of SDF-1 to CXCR4 induced intracellular signaling through several divergent pathways, including MAPK, PI3K-AKT-NF-κB and JAK-STAT pathways (30) . Based on the results of pathway analysis, we examined whether p38 MAPK pathway was involved in the suppressive effects of miR-9 by regulating CXCR4. C666-1 cells were transfected with indicated lentivirus and miR-9 inhibitors. When treated with SDF-1 in C666-1 cells, CXCR4 and p38 MAPK were activated (Figure 5D and E; Supplementary Figure 6 , available at Carcinogenesis Online). The activation of p38 MAPK was significantly enhanced by cotransfection with LV-CXCR4 or anti-miR-9 ( Figure 5F ). However, activation of ERK or JNK was not detected (data not shown). Thus, the miR-9-mediated silencing of CXCR4 led to the inactivation of the p38 MAPK pathway.
CXCR4 was upregulated in NPC specimens and inversely correlated with miR-9 levels
To gain further insights into the CXCR4 translational inhibition of miR-9 in NPC tissues, we analyzed CXCR4 level by immunohistochemical staining in the same collection of normal nasopharyngeal epithelial The transfected cells were incubated without or with SDF-1, and the cells were lysed and extracts were subjected to immunoblotting to examine the expression of CXCR4, p38 and phospho-p38. Fold activation of CXCR4 and p38 MAPK were shown in (E) and (F). **P < 0.001 compared with control. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. miR-9: a potential tumor suppressor tissues, primary tumors of locoregional NPC and metastatic NPC patients in which miR-9 levels were assessed by ISH. The results showed that CXCR4 was overexpressed in NPC, and its expression increased with the progression from locoregional to metastatic tumors ( Figure 6A and B). When the relative expression level of CXCR4 was plotted against that of miR-9 in each NPC sample, a significant inverse correlation was found (r = −0.693, P < 0.001; Figure 6C ). This reciprocal correlation further confirmed the regulation of CXCR4 by miR-9 in NPC.
To further test the CXCR4-mediated activation of p38 MAPK, we also assessed the expression of p38 and phospho-p38 in above tissue samples using immunohistochemical staining. The results showed that upregulation of CXCR4 was associated with activation of p38 MAPK in NPC samples ( Figure 6A and D) , and a significant inverse correlation was found between CXCR4 and phospho-p38 expression (r = −0.537, P < 0.001; Figure 6E ). However, the expression trend of p38 was different from that of CXCR4 (Supplementary Figure 7A , available at Carcinogenesis Online). Although p38 levels increased significantly in NPC tissues compared with control tissues (Supplementary Figure 7B , available at Carcinogenesis Online), there was no significant difference between locoregional tumors and metastatic tumors (Supplementary Figure 7C , available at Carcinogenesis Online).
Discussion
Although miR-9 has been reported to be involved in several other cancer types (12, (14) (15) (16) (17) (18) (19) (31) (32) (33) (34) (35) (36) , its role in NPC is largely unknown. To date, only one study has reported that miR-9 modulates the expression of interferon-regulated genes and major histocompatibility complex class I molecules in NPC cells (37) . The present study is the first report to explore the role of miR-9 in NPC tumorigenesis. We found that miR-9 was commonly downregulated in NPC specimens and NPC cell lines, and its reduced expression was inversely correlated with clinical stages and marked the progression from locoregional to metastatic tumors. These results suggested that miR-9 deregulation might be a common event in NPC and could serve as an independent prognostic marker to identify patients with poor outcome. However, further investigation is needed to confirm the prognostic value of miR-9 as an effective biomarker.
CpG islands hypermethylation is known as an epigenetic aberration leading to the inactivation of tumor-suppressive miRNAs in cancer cells (6) . To address the potential mechanisms underlying miR-9 downregulation in NPC, we explored the promoter methylation status of the mir-9-1, mir-9-2 and mir-9-3 gene loci in NPC cells and tissues. Aberrant hypermethylation was shown for mir-9-1, mir-9-2 and mir-9-3 loci in NPC cells and tissues, and demethylation treatment could restore miR-9 expression. The data were consistent with the findings in other cancers, including acute lymphoblastic leukemia, non-smallcell lung cancer, colorectal cancer, oral and oropharyngeal squamous cell carcinoma and renal cell carcinoma (15) (16) (17) (18) (19) (20) .
Interestingly, three independent miR-9 loci were differentially modified by DNA methylation in NPC tissues. We found that mir-9-1 loci was hypermethylated in both NPC and control tissues, while the methylation frequencies of mir-9-2 and mir-9-3 were much higher in NPC than in control tissues. Moreover, we identified that miR-9 was mainly expressed from mir-9-2 by detecting its precursors, and pri-miR-9-2 expression was markedly decreased in NPC tissues. Therefore, we speculated that mir-9-2 hypermethylation contributed more to miR-9 inactivation in NPC tissues. However, the molecular mechanism underlying the differential methylation modulators among the three miR-9 loci remains unknown. Recently, several advances have been made, leading to a leap forward in our understanding of the mechanisms by which DNA methylation is targeted to specific regions of the genome and interpreted by methyl-CpG-binding proteins. Brenner et al. (38) have shown that a direct interaction between DNMT3a and Myc is required for efficient repression of the Myc target gene p21. Another study from Di Croce et al. (39) suggested that an oncogenic fusion protein can recruit DNMTs and cause hypermethylation of target genes in cancer cells. These reports indicated that DNMTs could be targeted to endogenous genes by interaction with site-specific transcriptional repressor proteins (40) . Future studies are needed to uncover the protein-protein interactions, which might be important mediators of aberrant hypermethylation of miR-9 loci.
We also provide strong evidence that miR-9 functions as a tumor suppressor in NPC. Ectopic expression of miR-9 suppressed the proliferative, migratory and invasive capacities of NPC cells in vitro and in vivo. The data were similar to the findings in ovarian cancer, colon cancer and melanoma, in which miR-9 had been shown to inhibit tumor growth and metastasis and act as a putative tumor suppressor (13, 35, 41) . However, miR-9 was reported to be overexpressed in breast, cervical, brain and endometrial cancers, and its overexpression was correlated with cancer progression, metastasis and poor prognosis (12, 14, 32, 34) . These controversial results suggested that miR-9 was expressed in a tissue-specific pattern and had cell content-dependent functions.
A complex network of chemokines and their receptors influences the development of primary tumors and metastases. Recent studies have clearly shown that CXCR4 is implicated in tumor metastasis to distant organs via blood vessels in several tumor models, including melanoma metastasis to lung, prostate cancer metastasis to bone and neuroblastoma metastasis to bone marrow (42) . Here, we demonstrate CXCR4, a key metastasis promoter, as a novel target of miR-9 in NPC cells. Our results revealed that CXCR4 was overexpressed in NPC tissues and its expression increased with progression from locoregional to metastatic NPC, consistent with the published data (23, 43, 44) . Functional studies showed that overexpression of CXCR4 promoted cell proliferation, migration and invasion in vitro and in vivo (data not shown). Thus, our findings identify downregulation of miR-9 as an important mechanism of upregulation of CXCR4 in NPC cells that contributes to malignancy of NPC.
Molecular mechanisms contributing to NPC pathogenesis have been extensively investigated, and deregulated cell signaling pathways, including MAPK, PI3K/AKT, epidermal growth factor receptor and Wnt pathways, have been found to play pivotal roles in NPC carcinogenesis and progression (45) . Among them, the activated MAPK signals are well-accepted pro-proliferative pathway in NPC. Our results showed that the tumor-suppressive effect of miR-9 was mediated by inhibition of CXCR4 and downstream p38 MAPK pathway in SDF-1 stimulated cells. In clinical specimens, the levels of CXCR4 were inversely correlated with miR-9 or phospho-p38 expression. Previous reports found that SDF-1/CXCR4 axis exerted a promigratory effect in myeloid bone marrow-derived cells by activating p38 MAPK (46) and mediated cell migration by activating PI3K/Akt/mTOR pathway in human gastric carcinoma cells (47) . Therefore, there may be other molecules or signaling pathways, which are also targeted by miR-9, and some of them may be still unknown in NPC. Although our data strongly suggest that SDF-1/CXCR4 axis activated p38, but the exact mechanism is unknown. Therefore, it will be important to perform further investigations to identify additional signaling modulators and pivotal regulatory mechanisms of miR-9 in NPC progression.
In summary, we demonstrated that miR-9 was consistently downregulated in NPC specimens, and its expression was significantly associated with progression and metastasis of NPC. Functional analyses identified miR-9 as a potential tumor suppressor in the development and progression of NPC by targeting the key metastasis promoter CXCR4. Our results provide evidence for miR-9 as a potential metastatic marker and therapeutic target in treatment of NPC.
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